NCT05077332 - LEAP-CT for Treatment of COVID-19 Patients (Master Protocol) | Biotech Hunter

Enrollment

2,000

Participants

Timeline

Start Date

December 29, 2021

Primary Completion Date

October 31, 2025

Study Completion Date

December 31, 2025

Conditions

2019 Novel Coronavirus Disease2019 Novel Coronavirus Infection2019-nCoV Disease2019-nCoV InfectionCOVID-19 PandemicCOVID-19 Virus DiseaseCOVID-19 Virus InfectionCovid19Coronavirus Disease 2019SARS-CoV-2 InfectionSARS-CoV-2 Acute Respiratory DiseaseCOVID-19

Interventions

DRUG

Famotidine

80 mg tablet, QID for 14 days

DRUG

Celecoxib

400 mg (initial dose) then 200 mg capsule, BID for 5 days

OTHER

Placebo

tablet, QID for 14 days; capsule, BID for 5 days

Trial Locations (1)

33126

US02-04: Integrated Health Solutions, Miami